El papel de la Medicina Familiar y Comunitaria en el uso medicinal de cannabis
DOI:
https://doi.org/10.5712/rbmfc18(45)3632Palabras clave:
Cannabis, Marihuana Medicinal, Medicina Familiar y Comunitaria, Atención primaria de salud.Resumen
El uso medicinal del Cannabis tiene registros históricos que datan de aproximadamente 3.000 años antes de Cristo y ha persistido en varios momentos de la historia. Los estudios clínicos sobre este uso comenzaron en la década de los 60 del siglo XX, pero la investigación fue interrumpida debido a la política prohibicionista del uso del Cannabis, reconocido como una droga ilícita. El retorno de las investigaciones en la década de 1990 confirmó los efectos terapéuticos de esta planta, convirtiéndola en un potencial recurso medicinal a ser ofrecido por el Sistema Único de Salud con acceso desde la Atención Primaria de Salud. Con este ensayo nos proponemos reflexionar sobre el papel de la Medicina Familiar y Comunitaria como especialidad relevante en el manejo terapéutico del cannabis medicinal. Esta reflexión se basa en los principios de la especialidad y del Sistema Único de Salud, así como en la evidencia clínica sobre el uso médico de la marihuana.
Descargas
Métricas
Citas
Mechoulam R. Conversation with Raphael Mechoulam. Addiction 2007;102(6):887-93. https://doi.org/10.1111/j.1360-0443.2007.01795.x DOI: https://doi.org/10.1111/j.1360-0443.2007.01795.x
Zuardi AW. History of cannabis as a medicine: a review. Braz J Psychiatry 2006;28(2):153-7. https://doi.org/10.1590/s1516-44462006000200015 DOI: https://doi.org/10.1590/S1516-44462006000200015
Pertwee RG, Howlett AC, Abood ME, Alexander SP, Di Marzo V, Elphick MR, et al. International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂. Pharmacol Rev 2010;62(4):588-631. https://doi.org/10.1124/pr.110.003004 DOI: https://doi.org/10.1124/pr.110.003004
Sanchez-Ramos J. The entourage effect of the phytocannabinoids. Ann Neurol 2015;77(6):1083. https://doi.org/10.1002/ana.24402 DOI: https://doi.org/10.1002/ana.24402
Karst M, Salim K, Burstein S, Conrad I, Hoy L, Schneider U. Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: a randomized controlled trial. JAMA 2003;290(13):1757-62. https://doi.org/10.1001/jama.290.13.1757 DOI: https://doi.org/10.1001/jama.290.13.1757
Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A, et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 2003;362(9395):1517-26. https://doi.org/10.1016/S0140-6736(03)14738-1 DOI: https://doi.org/10.1016/S0140-6736(03)14738-1
Vaney C, Heinzel-Gutenbrunner M, Jobin P, Tschopp F, Gattlen B, Hagen U, et al. Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study. Mult Scler 2004;10(4):417-24. https://doi.org/10.1191/1352458504ms1048oa DOI: https://doi.org/10.1191/1352458504ms1048oa
Rog DJ, Nurmikko TJ, Friede T, Young CA. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 2005;65(6):812-9. https://doi.org/10.1212/01.wnl.0000176753.45410.8b DOI: https://doi.org/10.1212/01.wnl.0000176753.45410.8b
Hoggart B, Ratcliffe S, Ehler E, Simpson KH, Hovorka J, Lejčko J, et al. A multicentre, open-label, follow-on study to assess the long-term maintenance of effect, tolerance and safety of THC/CBD oromucosal spray in the management of neuropathic pain. J Neurol 2015;262(1):27-40. https://doi.org/10.1007/s00415-014-7502-9 DOI: https://doi.org/10.1007/s00415-014-7502-9
Thiele EA, Marsh ED, French JA, Mazurkiewicz-Beldzinska M, Benbadis SR, Joshi C, et al. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2018;391(10125):1085-96. https://doi.org/10.1016/S0140-6736(18)30136-3 DOI: https://doi.org/10.1016/S0140-6736(18)30136-3
Devinsky O, Patel AD, Cross JH, Villanueva V, Wirrell EC, Privitera M, et al. Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome. N Engl J Med 2018;378(20):1888-97. https://doi.org/10.1056/NEJMoa1714631 DOI: https://doi.org/10.1056/NEJMoa1714631
Almog S, Aharon‐Peretz J, Vulfsons S, Ogintz M, Abalia H, Lupo T, et al. The pharmacokinetics, efficacy, and safety of a novel selective-dose cannabis inhaler in patients with chronic pain: a randomized, double-blinded, placebo-controlled trial. Eur J Pain 2020;24(8):1505-16. https://doi.org/10.1002/ejp.1605 DOI: https://doi.org/10.1002/ejp.1605
Miller I, Scheffer IE, Gunning B, Sanchez-Carpintero R, Gil-Nagel A, Perry MS, et al. Dose-ranging effect of adjunctive oral cannabidiol vs placebo on convulsive seizure frequency in dravet syndrome: a randomized clinical trial. JAMA Neurol 2020;77(5):613-21. https://doi.org/10.1001/jamaneurol.2020.0073 DOI: https://doi.org/10.1001/jamaneurol.2020.0073
Müller-Vahl KR, Schneider U, Koblenz A, Jöbges M, Kolbe H, Daldrup T, et al. Treatment of Tourette's syndrome with Delta 9-tetrahydrocannabinol (THC): a randomized crossover trial. Pharmacopsychiatry 2002;35(2):57-61. https://doi.org/10.1055/s-2002-25028 DOI: https://doi.org/10.1055/s-2002-25028
Müller-Vahl KR, Schneider U, Prevedel H, Theloe K, Kolbe H, Daldrup T, et al. Delta 9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: a 6-week randomized trial. J Clin Psychiatry 2003;64(4):459-65. https://doi.org/10.4088/jcp.v64n0417 DOI: https://doi.org/10.4088/JCP.v64n0417
Duran M, Pérez E, Abanades S, Vidal X, Saura C, Majem M, et al Preliminary efficacy and safety of an oromucosal standardized cannabis extract in chemotherapy-induced nausea and vomiting. Br J Clin Pharmacol 2010;70(5):656-63. https://doi.org/10.1111/j.1365-2125.2010.03743.x DOI: https://doi.org/10.1111/j.1365-2125.2010.03743.x
Naftali T, Lev LB, Yablecovitch D, Half E, Konikoff FM. Treatment of Crohn's disease with cannabis: an observational study. Isr Med Assoc J 2011;13(8):455-8. PMID: 21910367
Crippa JA, Derenusson GN, Ferrari TB, Wichert-Ana L, Duran FL, Martin-Santos R, et al. Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. J Psychopharmacol 2011;25(1):121-30. https://doi.org/10.1177/0269881110379283 DOI: https://doi.org/10.1177/0269881110379283
Leweke FM, Piomelli D, Pahlisch F, Muhl D, Gerth CW, Hoyer C, et al. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry 2012;2(3):e94. https://doi.org/10.1038/tp.2012.15 DOI: https://doi.org/10.1038/tp.2012.15
Naftali T, Bar-Lev Schleider L, Dotan I, Lansky EP, Sklerovsky Benjaminov F, Konikoff FM. Cannabis induces a clinical response in patients with Crohn's disease: a prospective placebo-controlled study. Clin Gastroenterol Hepatol 2013;11(10):1276-80.e1. https://doi.org/10.1016/j.cgh.2013.04.034 DOI: https://doi.org/10.1016/j.cgh.2013.04.034
McGuire P, Robson P, Cubala WJ, Vasile D, Morrison PD, Barron R, et al. Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: a multicenter randomized controlled trial. Am J Psychiatry 2018;175(3):225-31. https://doi.org/10.1176/appi.ajp.2017.17030325 DOI: https://doi.org/10.1176/appi.ajp.2017.17030325
Bahorik AL, Sterling SA, Campbell CI, Weisner C, Ramo D, Satre DD. Medical and non-medical marijuana use in depression: longitudinal associations with suicidal ideation, everyday functioning, and psychiatry service utilization. J Affect Disord 2018;241:8-14. https://doi.org/10.1016/j.jad.2018.05.065 DOI: https://doi.org/10.1016/j.jad.2018.05.065
Pretzsch CM, Voinescu B, Mendez MA, Wichers R, Ajram L, Ivin G, et al. The effect of cannabidiol (CBD) on low-frequency activity and functional connectivity in the brain of adults with and without autism spectrum disorder (ASD). J Psychopharmacol 2019;33(9):1141-8. https://doi.org/10.1177/0269881119858306 DOI: https://doi.org/10.1177/0269881119858306
Pretzsch CM, Freyberg J, Voinescu B, Lythgoe D, Horder J, Mendez MA, et al. Effects of cannabidiol on brain excitation and inhibition systems; a randomised placebo-controlled single dose trial during magnetic resonance spectroscopy in adults with and without autism spectrum disorder. Neuropsychopharmacology 2019;44(8):1398-405. https://doi.org/10.1038/s41386-019-0333-8 DOI: https://doi.org/10.1038/s41386-019-0333-8
Hurd YL, Spriggs S, Alishayev J, Winkel G, Gurgov K, Kudrich C, et al. Cannabidiol for the reduction of cue-induced craving and anxiety in drug-abstinent individuals with heroin use disorder: a double-blind randomized placebo-controlled trial. Am J Psychiatry 2019;176(11):911-22. https://doi.org/10.1176/appi.ajp.2019.18101191 DOI: https://doi.org/10.1176/appi.ajp.2019.18101191
de Faria SM, de Morais Fabrício D, Tumas V, Castro PC, Ponti MA, Hallak JE, et al. Effects of acute cannabidiol administration on anxiety and tremors induced by a Simulated Public Speaking Test in patients with Parkinson's disease. J Psychopharmacol 2020;34(2):189-96. https://doi.org/10.1177/0269881119895536 DOI: https://doi.org/10.1177/0269881119895536
Grimison P, Mersiades A, Kirby A, Lintzeris N, Morton R, Haber P, et al. Oral THC:CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: a randomised, placebo-controlled, phase II crossover trial. Ann Oncol 2020;31(11):1553-60. https://doi.org/10.1016/j.annonc.2020.07.020 DOI: https://doi.org/10.1016/j.annonc.2020.07.020
Carneiro H. Drogas: a história do proibicionismo. São Paulo: Autonomia Literária; 2018. 541 p.
Barros A, Peres M. Proibição da maconha no Brasil e suas raízes históricas escravocratas. Periferia 2011;3(2):2-21. https://doi.org/10.12957/periferia.2011.3953 DOI: https://doi.org/10.12957/periferia.2011.3953
Gusso G, Lopes JMC, Dias LC. Tratado de Medicina de Família e Comunidade. 2ª ed. Porto Alegre: Artmed; 2018.
Freeman T, McWhinney IR. McWhinney’s textbook of family medicine. 4ª ed.New York: Oxford University Press; 2016. 520 p.
Brandão M. Em Marcha: maconha e a reversão de um estigma. Praça Rev Discente Pós-grad Em Sociol UFPE 2017;1(1):47–69.
Brasil. Projeto de lei n.º 399-A, de 2015 (do Sr. Fábio Mitidieri) [Internet]. 2015 [acessado em 20 jun. 2022]. Disponível em: em: https://www.camara.leg.br/proposicoesWeb/prop_mostrarintegra;jsessionid=node01vstr0jr2h1es9r68blsy6yh22291316.node0?codteor=2027392&filename=Avulso+-PL+399/2015
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
Derechos de autor 2023 Rubens Cavalcanti Freire da Silva, Georgia Leal Cesar de Albuquerque
Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.
Al enviar un manuscrito al RBMFC, los autores conservan la propiedad de los derechos de autor del artículo y autorizan a RBMFC a publicar ese manuscrito bajo la licencia Creative Commons Attribution 4.0 e identificarse como el vehículo de su publicación original.
